Eisai rises on top-line results for Lenvima in patients with differentiated thyroid cancer

12 August 2020

Shares of Japanese drugmaker Eisai (TYO: 4523) closed up 13.7% at 9.811 yen yesterday, after it announced top-line results from Study 211, a Phase II trial evaluating the efficacy and safety of Lenvima (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, comparing two starting doses (18mg versus 24mg daily) in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).

Results indicate that the lower starting dose (18mg) of Lenvima did not meet the non-inferiority requirement compared to the approved starting dose (24mg) in patients with RAI-refractory DTC as measured by objective response rate (ORR) at week 24. The data from this study support the selection of 24mg as an appropriate starting dose for patients with RAI-refractory DTC.

Study objectives

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK